New drug cocktail aims to shrink Hard-to-Treat colorectal tumors
NCT ID NCT07714447
First seen Jul 20, 2026 · Last updated Jul 22, 2026 · Updated 2 times
Summary
This phase 2 trial tests whether combining the experimental drug tunlametinib with other targeted therapies can shrink tumors or slow cancer growth in people with metastatic colorectal cancer that has worsened after at least one prior treatment. Participants are grouped based on their tumor's genetic profile and receive one of several drug combinations. The study measures how many patients respond and how long the benefit lasts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of tunlametinib (a MEK inhibitor) with cetuximab β (an EGFR inhibitor) and/or tislelizumab (a PD-1 inhibitor), and possibly another BRAF inhibitor
- What this could lead to
- If successful, this could offer a new treatment option for people with advanced colorectal cancer that has stopped responding to standard therapies.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the results may not confirm effectiveness or safety. Combination therapies also carry a higher risk of side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAF are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Sun Yat-sen University
Guangzhou, Guangdong, 510000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged antibody boost chemo against Hard-to-Treat colorectal cancer?
- Real-World data on colorectal cancer: what happens to patients over time?
- Engineered immune cells take on Hard-to-Treat colorectal cancer
- AI aims to improve colon polyp measurement for cancer prevention
- Chatbot boosts cancer screening uptake in hong kong trial
- New drug targets tough cancers in early trial